Molnupiravir, an antiviral drug used to treat patients with COVID-19, appears to be driving SARS-CoV-2 to mutate and evolve, with some of these new viruses being transmitted onwards, a new study has shown. It is not clear, however, whether these mutated viruses pose an increased risk to patients or are able to evade the vaccine.

Cambridge scientists have identified a signature in the blood that could help predict how well an individual will respond to vaccines. The discovery, published today in Nature Communications, may explain why, even among vulnerable patient groups, some individuals have better responses to vaccines than others.

A Department of Medicine Research Impact Case from the School of Clinical Medicine REF Submission Cambridge-led trials spanning two decades have tested and led to the use of alternative, less-toxic maintenance treatments for anti-neutrophil cytoplasm antibody associated vasculitis (AAV), a group of rare but aggressive diseases that cause inflammation of blood vessels with the restricted […]

Cambridge journal ‘Disease Models and Mechanisms’ publish interview with Professor Lalita Ramakrishnan to coincide with World TB Day (WHO) Professor Lalita Ramakrishnan is at the forefront of modern tuberculosis (TB) research. She has developed vital tools, most notably a robust zebrafish model, to study this disease, leading to seminal discoveries uncovering bacterial and host interactions […]

A Cambridge institute dedicated to improving cardiovascular and lung health has received a £16 million gift from Canadian entrepreneur and philanthropist Dr Victor Dahdaleh.